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Background: Growing evidence shows that herb medicines have some anti-osteoporotic effects, the mechanism
underlying is unknown. This study aims to investigate the therapeutic effect of Chinese herb supplements on rats
that had osteoporosis-like symptom induced by ovariectomy (OVX).
Methods: OVX or sham operations were performed on virgin Wistar rats at three-month old, which were randomly
divided into eight groups: sham (sham); OVX control group (OVX); OVX rats with treatments [either diethylstilbestrol
(DES) or Semen Astragali Complanati decoction (SACD) or Rhizoma Cibotii decoction (RCD) or Herba Cistanches
decoction (HCD) or Semen Allii Tuberosi decoction (SATD)]. Non-surgical rats were served as a normal control (NC).
The treatments began 4 weeks after surgery, and lasted for 12 weeks. Bone mass and its turnover were analyzed by
histomorphometry. Levels of protein and mRNA of osteoprotegerin (OPG) and receptor activator of nuclear factor
κB ligand (RANKL) in osteoblasts (OB) and bone marrow stromal cells (bMSC) were evaluated by
immunohistochemistry and in situ hybridization.
Results: Compared to OVX control, TBV% in both SACD and RCD groups was increased significantly, while TRS%,
TFS%, MAR, and mAR were decreased remarkably in the SACD group, only TRS% decreased dramatically in the RCD
group. No significant changes in bone formation were observed in either HCD or SATD groups. OPG levels in both
protein and mRNA were reduced consistantly in OB and bMSC from OVX control rats, in contrast, RANKL levels in
both protein and mRNA were increased significantly. These effects were substantially reversed by treatments with
either DES or SACD or RCD. No significant changes in both OPG and RANKL expression were observed in OB and
bMSC from OVX rats treated with SATD and HCD.
Conclusions: Our study showed that SACD and RCD increased bone formation by stimulating OPG expression and
downregulating RANKL expression in OB and bMSC. This suggests that SACD and RCD may be developed as
alternative anti-osteoporotic agents for therapy of postmenopausal osteoporosis.Background
Osteoporosis often occurs in postmenopausal women, and
older men. Osteoporosis is a systemic skeletal disease
characterized by low bone mass and microarchitectural
deterioration of bone tissue, leading to an increased
risk fragility fractures [1]. Bone remodeling is normal* Correspondence: gxiao@creighton.edu; judahong@sohu.com
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reproduction in any medium, provided the orphysiological processes of bone that is governed by two
counter-processes, bone formation and resorption [2-5].
Currently, available therapies developed for osteopor-
osis are based on a strategy, which compounds either
reduce the rate of resorption or promote bone forma-
tion, including bisphosphonates, calcitonin, estrogens,
and hormone replacement therapy (HRT). Although
these medications are still in use clinically for preven-
tion or treatment of osteoporosis, they often have
unwanted side effects. Although HRT remains good
treatments for preventing osteoporosis still, these drugs
can stimulate endometrial hyperplasia and increase theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therefore, it is urgent to develop an alternative strategy
for prevention and treatment of osteoporosis.
Herb medicines have been long used for treatment of
osteoporosis in China. According to the theory of the
traditional Chinese medicine, kidneys are organs that
can usually strengthen the foundation of the essence,
regulate development of bones, and stimulate growth of
bone marrow. Well-functioned kidneys promote growth
of bone marrow, resulting in strength of bones. In con-
trast, weakly-functioned kidneys often cause develop-
ment of bone poorly, resulting in an osteoporosis-like
symptom, such as lumbar and back pain, leading to an
increased risk of bone fragility fractures. Therefore,
osteoporosis in China has been treated by using herb
supplementation, which it is believed to restore kidneys’
function effectively (Chinese reference may not be pro-
vided here).
Use of herb medicines for treatment of osteoporosis
has been well documented for long history in China.
However, the anti-osteoporotic mechanisms are still un-
known. Our previous studies suggest that Chinese herbs
increased bone formation by stimulating OPG expres-
sion and downregulating RANKL in bone marrow cells
[8]. The anti-osteoporotic effects are selective for these
herbs. For example, among herb medicines studied in
the previous study, only Radix Dipsaci and Pyrola Herb
had significant anti-osteoporotic effects [8]. To develop
the most effective herb medicine as an alternative
treatment for osteoporosis, in this study we selected
additional four herbs, Semen Astragali Complanati,
Rhizoma Cibotii, Herba Cistanches, and Semen Allii
Tuberosi, from 24 Chinese herbs available in Chinese
clinics. The criteria for selection of these herb medi-
cines are based on: 1) those potentially effective for
therapy of osteoporosis by ancient Chinese medical
documents (Chinese reference, not listed here); and
2) those shown mostly effective for therapy of osteo-
porosis in our previous cell culture and in vivo stu-
dies (Chinese reference, not listed here).
The OPG/RANKL/RANK signaling pathway has
been extensively studied as a molecular model for
evaluation of drug efficacy and for understanding
molecular mechanism of anti-osteoporosis in animals
and humans [9-12]. The mechanism underlying the
anti-osteoporotic effects of herb medicines is largely
unknown. In this study, we investigated how Chinese
herb medicines, especially those “kidney-supplements”,
such as Semen Astragali Complanati, Rhizoma Cibotii
decoction, Herba Cistanches, and Semen Allii Tuberosi,
affected bone development, which was examined by
measuring the activity of OPG/RANKL/RANK signal-
ing in rats that had osteoporosis-like symptom induced
by OVX.Methods
Identification and preparation of extracts
Semen Astragali Complanati (SAC) was the dried mature
seed of Astragalus complanatus R.Br. produced in China,
and collected by Tianjian Medcial Co. Ltd. Wanfang
Branch (Shanxi, China) in March 2007, and identified
and authenticated by an expert herbalist at the Institute of
Chinese Materia Medica, China Academy of Chinese
Medical Sciences (CACMS).
Rhizoma Cibotii (RC) was the dried root stalk of
Cibotium barometz (L.) J. Sm. produced in China, and
collected by Zhonghong Herbal Drug Co. Ltd. (Sichuan,
China) in March 2007, identified and authenticated by
an expert herbalist at the Institute of Chinese Materia
Medica, CACMS.
Herba Cistanches (HC) was the dried fleshy stem of
Cistanche deserticola Y. C. produced in China, and
collected by Taizhou Herbal Drug Co. Ltd. (Zhejiang,
China) in March 2007, identified and authenticated by
an expert herbalist at the Institute of Chinese Materia
Medica, CACMS.
Semen Allii Tuberosi (SAT)was the dried mature
seed of Allium tuberosum Rottl produced in China,
and collected by Huarui Medcial Co. Ltd. (Hubei,
China) in March 2007, identified and authenticated by
an expert herbalist at the Institute of Chinese Materia
Medica, CACMS.
All the dried herbs after collection were stored in a
dry and sealed container at 4°C to prevent herbs from
moisture and moth. SACD, RCD, HCD, and SATD were
extracted from the herbs by boiling 300 gram of the
dried SAC, RC, HC, and SAT in a 6-litre water at 100°C
for 2 h. Each decoction was then concentrated to a final
concentration of 1 crude drug gram per milliliter.
The voucher specimens of the plant materials used in
this study were deposited in the herbarium of Institute
of Chinese Materia Madica China Academy of Chinese
Medical Sciences. The deposition number is 37B for
Semen Astragali Complanati, 13A for Rhizoma Cibotii,
10A for Herba Cistanches, and 40A for Semen Allii
Tuberosi.
Animals and experimental procedures
Ninety-four virgin Wistar female rats (weight 250 ±
20.0 g) were obtained from the Experimental Animal
Center of the Academy of Military Medical Sciences
(Beijing, China), and were housed in cages in the experi-
mental animal facility at the Institute of Basic Theory of
TCM, CACMS. The rats were maintained at 22°C with a
12 h light/dark cycle. During the experiment, the rats
were maintained on standard rodent chow (Animal
Center of the Fourth Military Medical University, Xi’an,
China) that contained 0.9% calcium and 0.7% phos-
phate; distilled water was available ad libitum.
Table 1 The primer sequence used in the experiments
(BORSTER, China)
Target Primer sequence (5′-3)′
OPG (1)5′ -TGGAC AACCC AGGAA ACCTT TCCTC CAAAA-3′,
(2)5′ -TTTGC CTGGG ACCAA AGTGA ATGCA GAGAG-3′,
(3)5′ -AGAAA TGATA GGGAA TCAGG TTCAA TCAGT-3′.
RANKL (1)5′-GCCAG CCGAG ACTAC GGCAA GTACC TGCGC-3′,
(2)5′-GGCCA GGTGG TCTGC AGCAT CGCTC TGTTC-3′,
(3)5′-TTTAT AGAAT CCTGA GACTC CATGA AAACG-3′.
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anormal control (NC) group (n = 12), sham control group
(n = 12), and a bilaterally ovariectomized (OVX, n = 70)
group using the dorsal approach7. OVX rats were
randomly divided into six groups, including OVX group
(n = 12), DES group (n = 12), SACD group (n = 12), RCD
group (n = 12), HCD group (n = 11), and SATD group
(n = 11). Diethylstilbestrol 0.008 mg/ml dissolved in dis-
tilled water was administered intragastrically to the rats in
the DES group. The rats of the SACD, RCD, HCD, and
SATD groups were treated with SACD 5.6 ml/ (kg body
weight day), RCD 5.6 ml/ (kg body weight day), HCD
5.6 ml/ (kg body weight day), and SATD 5.6 ml/ (kg body
weight day), respectively. At the same time, the rats
of the NC, sham control, and OVX groups wereFigure 1 Effects of herbs on trabecular bone formation. The undecalci
herb suplements on bone. The red arrow indicates trabecular bone. Pleaseadministered with the same volume of distilled water.
The treatment started four weeks after the surgery and
continued for 12 weeks.
On the fifteenth and the third days before sacrifice, all
the rats received tetracyclin 30 mg/kg by intraperitoneal
injection. After sacrifice, proximal right tibiae were
fixed in 4% paraformaldehyde for 24 h and dehydrated
through an ethanol gradient of 80%, 90%, and 100%
ethanol, with two days for each step. Dehydrated
samples were defatted in xylene for two days before be-
ing embedded in a plastic polymer solution I (Methyl
Methacrylate Monomer 100 ml + Butyl Methacrylate
35 ml +Methyl Benzoate 5 ml + Polyglycol 1.2 ml), solu-
tion II (solution I + Drying Benzoyl Peroxide 0.4 g) and
solution III (solution II + Drying Benzoyl Peroxide 0.8 g)
with three days for each step. Each undecalcified sample
was sliced into two 5 μm longitudinal sections with
microtome (Reichert-Jung 2040, Ger). One section was
stained with toluidine blue and the other was used
for fluorescence morphology observation. Proximal left
tibiae were fixed in 4% paraformaldehyde for 24 h and
decalcified in a solution of 10% EDTA (PH7.36) at 4°C
for three weeks. After that, decalcified samples were
dehydrated in 15% sucrose solution for 10 h. Each sam-
ple was sliced into 5 μm sections by freezing microtome
(OM2563, TBS, CA). Frozen sections were fixed infied bone sections were obtained to estimate the effects of Chinese
see Methods section in the text for details.
Table 2 Effects of SACD, RCD, HCD, and SATD on the percentage of trabecular bone volume (TBV%), the percentage of
trabecular bone resorption surface (TRS%), the percentage of trabecular bone formation surface (TFS%), 14Hbone
mineral apposition rate (MAR), the membrane bone mineral apposition rate (mAR), and the osteoid average width
(OSW) of tibia from rats
Group n TBV% TRS% TFS% MAR(μm/d) mAR(μm/d) OSW(μm)
NC 12 28.08 ± 7.26 3.56 ± 1.47 8.23 ± 2.69 1.30 ± 0.18 2.40 ± 0.54 5.65 ± 1.34
Sham 12 27.18 ± 8.78 3.40 ± 1.54 7.40 ± 2.41 1.38 ± 0.16 2.28 ± 0.47 6.20 ± 1.29
OVX 12 8.945 ± 3.04b 9.31 ± 2.22b 14.54 ± 3.31b 1.86 ± 0.23b 3.03 ± 0.60b 7.77 ± 1.64a
DES 12 23.61 ± 4.71d 3.28 ± 1.31d 7.72 ± 2.66d 1.32 ± 0.22d 2.15 ± 0.70d 6.37 ± 1.42c
SACD 12 21.15 ± 4.97d 4.71 ± 1.57d 9.70 ± 2.29a, d 1.55 ± 0.26d 2.61 ± 0.31c 6.88 ± 1.56
RCD 12 12.10 ± 4.15b, c 7.11 ± 1.58b, c 14.93 ± 3.50b 1.92 ± 0.32b 3.09 ± 0.66b 7.13 ± 1.82
HCD 11 8.86 ± 2.64b 10.31 ± 2.61b 12.47 ± 3.92b 1.78 ± 0.17b 3.05 ± 0.76b 7.53 ± 1.86
SATD 11 10.84 ± 3.28b 10.06 ± 2.37b 12.41 ± 2.91b 1.82 ± 0.29b 2.96 ± 0.56b 6.28 ± 1.82
aCompare with sham control group: P < 0.05.
bCompare with sham control group: P < 0.01.
cCompare with OVX group: P < 0.05.
dCompare with OVX group: P < 0.01.
Figure 2 Effects of herbs on protein expression of OPG and RANKL in osteoblasts and marrow stromal cells from tibia of rats.
Expression level of OPG and RANKL was estimated by immunohistochemical analysis. A) OPG expression, B) RANKL expression, and C) Ratio of
RANKL/OPG are shown. Please see Methods section in the text for details.
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Table 3 Effects of SACD, RCD, HCD, and SATD on the protein expression of OPG and RANKL in OB and bMSC from tibia
of rats
Group n The protein expression of
OPG in OB
The protein expression of
OPG in bMSC
The protein expression of
RANKL in OB
The protein expression of
RANKL in bMSC
NC 12 1.66 ± 0.42 7.18 ± 1.72 1.08 ± 0.27 4.77 ± 1.82
Sham 12 1.72 ± 0.52 6.48 ± 1.81 1.17 ± 0.28 4.55 ± 1.75
OVX 12 0.76 ± 0.23b 3.06 ± 1.28b 1.82 ± 0.41b 9.06 ± 2.11b
DES 12 1.62 ± 0.38d, c 6.24 ± 1.91d, c 1.23 ± 0.34d, c 5.34 ± 1.54d, c
SACD 12 1.51 ± 0.45d, c 5.70 ± 1.63d, c 1.30 ± 0.30d, c 6.40 ± 1.88a, d, c
RCD 12 1.25 ± 0.41a, d 4.63 ± 1.23b, d 1.77 ± 0.36b 8.04 ± 2.01b
HCD 11 0.72 ± 0.24b 3.10 ± 1.05b 1.87 ± 0.36b 9.14 ± 2.03b
SATD 11 0.94 ± 0.30b 3.60 ± 1.12b 1.75 ± 0.35b 8.74 ± 1.84b
aCompare with sham control group: P < 0.05.
bCompare with sham control group: P < 0.01.
cCompare with OVX group: P < 0.05.
dCompare with OVX group: P < 0.01.
Liu et al. BMC Complementary and Alternative Medicine 2013, 13:141 Page 5 of 9
http://www.biomedcentral.com/1472-6882/13/141acetone and were prepared for immunohistochemistry
and in situ hybridization. All animals were treated
according to the Guide for the Care and Use of Labora-
tory Animals and with the approval of the Institutional
Ethics Committee of CACMS on animal experiments.
Immunohistochemical assessment
Frozen sections were mounted on glass slides and used
for immunohistochemical analysis. Primary antibodies
[anti-rat OPG (1:1000) and anti-rat RANKL (1:1000)]
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The tissue slides were rinsed in PBS and
immersed in 0.3% hydrogen peroxide for 5 min, then, in-
cubated with the primary antibodies for 1h at 37°C, and
then rinsed with PBS three times for 3 min. The slides
were then incubated with the appropriated unbiotinylated
secondary antibody (Zhongshan Goldenbridge Biotech-
nology Co. Ltd., China) for 30 min at 37°C, followed by
incubation with a solution containing DAB (Zhongshan
Goldenbridge Biotechnology Co. Ltd., China) for 30 s,
then rinsed in running water. After that, the slides were
counterstained with Harris hematoxylin and sealed for
microscopic analysis. Non-immune goat serum instead of
the primary antibody was served as negative control.
All measurements were performed with the QWin
image analysis system (Leica Corp., Germany). Five ran-
dom images within tibiae from two sections were taken,
and further analyzed by using zoomed-in field at 400×
magnification. We measured the positive stained and
total area under each examined field for each section.
The positive stain of osteoblasts was calculated by using
the percentage of stained osteoblasts over the total tra-
becula area under each field. The positive stain of bMSC
was calculated by using the percentage of stained bMSC
over a marrow cavity area excluding trabecula.In situ hybridization
After warming-up, frozen sections were immersed in a so-
lution of 30% hydrogen dioxide and methanol for 30 min,
and incubated in a diluted pepsin solution (3% citric acid)
at 37°C for 10 min. After that, the sections were post-fixed
in 1% paraformaldehyde for 2 min. Sections were then in-
cubated with the DIG-labeled antisense cRNA probes (see
Table 1) at 40°C overnight in a humidified chamber, then
followed by performing multiple washes in 4 × SSC at
room temperature. Slides were incubated in a blocking re-
agent for 30 min at 37°C, then incubated with biotinylated
anti-digoxin antibody (Sigma, St. Louis, MO, USA) for
60 min, SABC (Wuhan Bpster Biological Technology Ltd,
Wuhan, China) for 20 min, and biotinylated peroxydase
for 20 min at 37°C, in order, and followed by staining
using DAB (Zhongshan Goldenbridge Biotechnology Co.
Ltd., China). Finally, sections were covered with glycerol-
gelatin and coverslips. For every hybridization procedure,
DIG-labeled cRNA sense probes were used as control to
rule out nonspecific binding.
Statistical analysis
All values were expressed as means ± standard deviations.
All analyses were carried out using the SAS 9.1.3 (Cary,
NC, USA). The difference between the groups was ana-
lyzed using the ANOVA test followed by the Tukey test.
Results
Effects of SACD, RCD, HCD, and SATD on tibia
After three months’ treatment, the right tibia of the OVX
rat was harvested, and the undecalcified bone sections
were used for bone morphometric analysis (Figure 1).
Figure 1 showed that the numbers of the trabecula in tibia
from the sham group were similar to those in WT rats,
but significantly higher than those in OVX control rats,
Figure 3 Effects of Chinese herbs on mRNA levels of OPG and RANKL in osteoblasts and marrow stromal cells from tibia of rats.
Messenger RNA levels of RANKL and OPG in tibia sections were examined by using in situ hybridization. A) OPG mRNA level, B) RANKL mRNA
level, and C) Ratio of mRNA RANKL/mRNA OPG are shown in this figure. All the experiments were performed three times. Please see the Methods
section in the text for details.
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bone. However, OVX-induced effect on bone loss was
remarkably reversed in rats treated with DES, SACD, or
RCD, but not with HCD or SATD.
Data from analysis of bone histomorphometry are shown
in Table 2. Compared to the sham group, the TBV% of the
tibia from rats decreased significantly by OVX. However,
the OVX effects on TBV% of the tibia were significantly
reversed, though not completely reversed, in OVX rats
treated with SACD, RCD, or DES, but not with HCD or
SATD (Table 2).
Although TRS%, TFS%, MAR, and mAR of tibia from
sham rats were similar to those from normal rats, these
indexes were significantly enhanced by OVX compared
to sham or normal rats. However, the OVX effects on
TRS%, TFS%, MAR, and mAR of the tibia weresignificantly alleviated, but not abolished, in rats treated
with SACD or DES, but not RCD, HCD, or SATD
(Table 2). Similarly, OSW of tibia was not significantly
different between sham and normal rats, but was sharply
increased by OVX. The OVX effect on OSW of the tibia
from rats was not changed by treatment with any of
herbs (Table 2).
Effects of SACD, RCD, HCD, and SATD on protein
expression of OPG and RANKL in OB and bMSC
After three-month treatment, expression of bone forma-
tion marker OPG in OB and bMSC from rat tibias was
examined by immunohistochemistry (Figure 2A). The
protein expression of OPG in OB and bMSC from rats
in the sham group was similarly highly expressed to that
in normal control, but was significantly lower in the
Table 4 Effect of SACD, RCD, HCD, and SATD on OPG and RANKL mRNA expression in * OB and bMSC from rats’ tibia








NC 12 2.07 ± 0.46 7.33 ± 1.82 1.47 ± 0.52 5.84 ± 1.69
Sham 12 2.15 ± 0.66 7.65 ± 2.19 1.60 ± 0.50 6.07 ± 1.79
OVX 12 1.05 ± 0.40b 3.30 ± 1.03b 2.41 ± 0.53b 9.94 ± 2.16b
DES 12 1.98 ± 0.40d 6.92 ± 1.65d 1.70 ± 0.48d 6.26 ± 1.67d
SACD 12 1.82 ± 0.36d 6.44 ± 1.69d 1.83 ± 0.44d 6.87 ± 1.71d
RCD 12 1.43 ± 0.43b, c 5.00 ± 1.46b, d 2.18 ± 0.52a 8.87 ± 1.91b
HCD 11 0.97 ± 0.36b 3.28 ± 1.20b 2.20 ± 0.60a 9.82 ± 1.95b
SATD 11 1.28 ± 0.38b 3.69 ± 1.47b 2.10 ± 0.48a 9.51 ± 1.86b
aCompare with sham control group: P < 0.05.
bCompare with sham control group: P < 0.01.
cCompare with OVX group: P < 0.05.
dCompare with OVX group: P < 0.01.
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OPG in OB and bMSC was alleviated in rats treated with
either DES or SACD, but not with HCD, SATD, or RCD
(Figure 2A). We calculated the OPG-positive stained area
using computer software and showed the results in
Table 3. Quantitative measurement of OPG expression
(Table 3) confirmed the observation in Figure 2A.
As expected, protein expression of the bone resorption
marker RANKL in OB and bMSC from rats in the sham
group was similar to that in normal control group.
OVX, however, remarkably induced RANKL expression
in OB and bMSC from rat tibias (Figure 2B). The OVX
effects on RANKL expression in OB and bMSC were
significantly reversed in rats treated with either SACD
or DES, but not with RCD, HCD, or SATD. The results
in Figure 2B were confirmed by quantitative results of
RANKL in tibia (Table 3).
The ratio of RANKL/OPG has been used as an index
for evaluation of activity of bone remodeling [13]. To
help visualize the effects of these Chinese herb supple-
ments on bone remodeling, we re-plotted the data from
Figure 2A/B in Figure 2C, of which the expression pat-
tern is similar to that in Figure 2A/B.
Effects of SACD, RCD, HCD, and SATD on OPG and RANKL
mRNA expression in OB and bMSC from tibia of
ovariectomized rats
To further understand whether these medicines affect
the mRNA level of OPG and its decoy factor RANKL in
OB and bMSC from rats’ tibias, we analyzed mRNA ex-
pression levels of OPG and RANKL in tibia sections
using in situ hybridization (Figure 3 and Table 4). OPG
mRNA expression in OB and bMSC from tibia of rats in
the sham group was highly expressed, and similar to that
in normal control group, but was remarkably down-
regulated by OVX treatment (Figure 3A). However,
OVX effect on OPG mRNA expression was significantly
alleviated in rats treated with SACD, RCD, or DES, butnot with HCD or SATD. This observation was con-
firmed by quantitative measurements of OPG mRNA in
OB and bMSC from tibia of rats (Table 4).
As expected, RANKL mRNA expression in OB and
bMSC from tibia of rats in the sham group remains low
and similar to that in the normal control group, but was
reduced significantly by OVX treatment (Figure 3B). How-
ever, OVX-caused effects on RANKL mRNA expression
were remarkably alleviated, although not recovered to the
level in normal control, in rats treated with either DES or
SACD, but not with RCD, HCD, or SATD (Figure 3B).
Results in Figures 3A/B were verified by quantitative mea-
surements of RANKL mRNA in OB and bMSC from tibia
of rats (Table 4).
To illustrate the effects of these Chinese herb supple-
ments on bone remodeling clearly, we re-plotted the data
from Figure 3A & B (Figure 3C) and found a similar pat-
tern to that in Figure 3A & B.
Discussion
Although Chinese mherbs have shown an effective thera-
peutic strategy for Chinese people. the exact mechanism
underlying is still unknown. Our previous study and
others showed that Radix Dipsaci decoction and Pyrola
Herb decoction enhanced significantly bone formation in
OVX rats [8,14]. Our results in this study showed that
Chinese herbs SACD and RCD increased bone formation
by stimulating OPG expression and downregulating
RANKL expression in OB and bMSC.
Resistance to bone fracture depends on its structure
and mechanic properties, which are maintained by
lifelong bone remodeling [15]. Bone remodeling is con-
trolled dynamically by two-counter balanced processes,
bone resorption and bone formation [2,3]. Interruption
of the counter-balanced processes leads to an abnormal
bone remodeling, resulting further in deterioration of
overall skeleton structure. Osteoporosis is highly regu-
lated by many factors including genetic background, age,
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nopausal women is developed incrweasingly due to
estrogen deficiency, which causes overexpression of
pro-inflammatory cytokines provoking activity of bone
resorption [16]. Discovery of OPG, RANKL, and RANK
has shed light on understanding of regulation of bone
modeling and remodeling [16]. OPG is one of the tumor
necrosis factor receptor (TNFR) superfamily members
[17], and a soluble glycoprotein secreted by various
mesenchymal-derived cells, such as osteoblasts [18] and
bone marrow stromal cells [19]. OPG acts as a soluble
decoy receptor for RANKL and, thus, decreases bone
resorption. RANKL is a TNF-related cytokine expressed
by various bone cells, including osteoblasts and their
immature precursors [12], activated T lymphocytes and
B lymphocytes [20]. RANKL is essential for mediating
bone resorption, which stimulates osteoclastogenesis
and osteoclast activity by binding to the osteoclast
surface receptor [20,21]. RANK is also a member of the
TNFR family [22] and is highly expressed by a wide
variety of cells, such as osteoclast precursors, mature
osteoclasts, B and T lymphocytes, dendritic cells, fibro-
blasts, and articular chondrocytes, and is considered as
a natural receptor of RANKL [21]. The binding of
RANKL to RANK leads to the activation of signaling
pathways, which regulates function of osteoclast. OPG
protects bone from excessive resorption by inhibition of
RANKLbinding to RANK [23]. Thus, the OPG/RANKL/
RANK signaling pathway is considered as a key cytokine
system for controlling bone modeling and remodeling.
In this study, we examined the herbal medicines’ effects
on bone morphometric indexes and OPG/RANKL ex-
pression in OB and bMSC from OVX rat tibia, and
found that only SACD, similar to DES treatment, can
alleviate the loss of tibia bone mass that was induced by
OVX treatment.
Previous studies demonstrated that overexpression of
OPG gene in mice resulted in high bone mass and a re-
markable reduction in osteoclast number and its activity,
while low BMD, increased numbers of osteoclasts and
more woven bone were observed in OPG knockout
(KO) mice [24]. Injection of recombinant RANKL and
OPG to mice caused a rapid and significant increase in
bone turnover signals (BTSs) and number of osteoclasts
[25]. One OPG injection resulted in a decreased BTS
within two hours, and a 50% to 60% reduction in osteo-
clast numbers within 12 to 24 hours [26]. Our experi-
ments showed that expression of OPG in OB and bMSC
from OVX rats treated with either SACD or RCD
was significantly higher than that from control, while
RANKL expression was much lower than that from
control, suggesting that SACD and RCD treatment
induced expression of OPG, but decreased RANKL
expression, in OB and bMSC.Intriguingly, we observed that the medicines tested in
this study showed similar effects to DES, suggesting that,
to some extent, these medicines may contain certain
amount of active components, such as phytoestrogen,
although the exact active components in these medicines
have not been isolated yet. Further functional charac-
terization of these active components from these me-
dicines, especially SACD, may be needed and helpful for
understanding the mechanism underlying the medicine-
induced effect.
Conclusions
Data from this study suggest that SACD enhanced bone
formation and decreased bone resorption significantly
in the treated OVX rats. The mechanism underlying
SACD-induced effects in OVX rats may be explained by
overexpression of bone formation marker OPG and
suppression of bone resorption marker RANKL in OB
and bMSC from rats’ tibia.
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